Michael A. Carson has recently been appointed as president and CEO of Centene Corporation’s Medicare business, Wellcare.
Carson, who succeeds Richard Fisher, will now be responsible for Medicare business performance, strategy and the growth of Wellcare.
Before serving nearly three decades in the healthcare industry, Carson began his career in the United States Air Force, where he served for almost a decade.
He has since developed an array of leadership, operational and industry skills in both the payer and provider space with a focus on serving Medicare and dual-eligible populations.
Carson previously held the positions of CEO at CareAbout, a value-based primary and multi-specialty care startup, as well as at Bright Health Plan and Harvard Pilgrim Health Care.
Additionally, he led the rebuilding of Medicare ventures at Amerigroup and Anthem, while also serving leadership positions at ConcertoHealth and various Blue Cross Blue Shield plans.
In a press release, Carson shared his excitement to support Wellcare’s mission to transform the health of the communities it serves.
"I look forward to helping guide the Medicare business to realize its full potential, driving further innovation and growth as we collaborate with our Medicaid and Marketplace businesses and key provider and member services partners," Carson said.
Wellcare health plans provide government-sponsored healthcare programs nationwide, with some states exclusively offering Prescription Drug Plans (PDP), while the majority offer both PDP and Medicare Advantage (MA) Plans.
Centene has expanded its Medicare presence in recent years, offering various MA products across 37 states. To enhance consumer’s healthcare experience, Centene invests in service initiatives for both members and brokers, providing affordable options for its Medicare beneficiaries.
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen
The Relationship Between ILD and MDA5 Antibody-Positive DM
May 2nd 2024Rapidly progressing interstitial lung disease in anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) is known for its high death rate because it worsens quickly and causes breathing difficulties within three months of initial lung symptoms. However, there isn't much information about the timing between the diagnosis of ILD and MDA5 antibody-positive DM because most research focuses on either the frequency or the death rates rather than the timing of onset.
Read More